CTLA4 and neoplasm: Rare but serious AEs, including myocarditis and myasthenia gravis, were also observed.300 This demonstrates the challenging balance between boosting anti-tumor immunity and maintaining immunological tolerance, which must be carefully controlled in patients receiving CTLA-4 inhibitors.